The literature on the gut–skin axis in canine atopic dermatitis (cAD) is young but converging on a coherent picture: dogs with allergic skin disease have measurably different gut flora than healthy controls, and the degree of that dysbiosis tracks with disease severity. Here's where the evidence stands:

Dysbiosis is a real finding in cAD

Baseline analysis revealed significantly lower gut microbial diversity in dogs with cAD than in healthy dogs. Differential abundance analysis showed that Fusobacterium, Megamonas, Collinsella, unclassified Clostridiales, Bacillus, Helicobacter, and Caproiciproducens were significantly more abundant in healthy dogs. 1

A separate Swiss preliminary cohort found a similar but not identical pattern: in healthy dogs, a higher abundance of the families Lachnospiraceae, Anaerovoracaceae and Oscillospiraceae and genera Lachnospira, Ruminococcus torques group, Fusobacterium and Fecalibacterium was seen, when compared to allergic dogs. The abundance of Conchiformibius, Catenibacterium spp., Ruminococcus gnavus group and Megamonas were higher in allergic dogs. 2 Note Megamonas falls on opposite sides in those two studies — flag for the inconsistency.

The Shiba Inu cohort confirmed the broader signal: dysbiosis of both the skin and the gut was observed in cAD in Shiba Inu dogs. 3

Severity scales with the degree of dysbiosis

This is the most clinically relevant point. Dogs with cAD not only exhibited gut microbiome dysbiosis but also demonstrated a significant negative correlation with microbial diversity as the symptoms worsened. The degree of dysbiosis and clinical scores were also significantly correlated. This suggests that the gut microbiota may act as a potential cause of cAD and contribute to the exacerbation of symptoms. Microbes that were negatively correlated with disease severity were Fusobacterium and Megamonas, genera that were depleted in dogs with cAD. 1

Counter-intuitively, the same study found a positive correlation between Lactobacillus and Bifidobacterium abundances and CADESI or PVAS, indicating that higher abundances of these typically beneficial microbes were associated with more severe atopic dermatitis. 1 — a reminder that the "good bacteria" framing from human probiotic literature doesn't map cleanly onto dogs.

Proposed mechanisms

The literature points to three overlapping pathways:

• Immune modulation via SCFAs. Compositional differences in the gut microbiome are associated with the development and severity of atopic dermatitis through immunologic, metabolic, and neuroendocrine pathways. The gut microbiota directly influences T cells, and it is known that short-chain fatty acids (SCFAs), produced by certain bacteria, can have an anti-inflammatory effect 4.
• Intestinal barrier dysfunction ("leaky gut"). AD and indeed any other 'skin disease', may be seen as a possible manifestation of a more systemic problem involving gut dysbiosis and increased intestinal permeability, which may occur even in the absence of gastrointestinal signs. Manipulation of the canine intestinal microbiota as a method for modifying atopy, may be attempted in many ways including avoidance of certain foods, supplementation with probiotics and prebiotics, optimising nutrient intake, minimising stress, antimicrobial therapy, correction and prevention of low stomach acid, and faecal microbiota transplantation (FMT). 5
• Direct intestinal epithelial damage. A Selçuk University study using serum biomarkers reported the development of atopic dermatitis may be predisposed to the entry of allergens into the body through sites of intestinal damage 6 — a small dataset (26 cAD vs 10 healthy) but consistent with the leaky-gut hypothesis from human medicine.

Therapeutic implications (still emerging)

• Probiotics: the Song 2025 study showed probiotic administration can effectively ameliorate cAD by improving gut microbial dysbiosis 1 — though small n and heterogeneous strains across the literature limit generalizability.
• Dietary modulation: an AJVR 2025 study reported clinical recovery in canine atopic dermatitis affected pet dogs via alteration of the gut microbiome, following a meat and egg exclusion diet for 60 days 7. Worth noting this conflates allergen elimination with microbiome remodelling — hard to separate the two effects.
• JAK inhibition does NOT shift gut flora: a 4-week treatment course with oclacitinib was not associated with changes in the gut microbiota diversity and composition in atopic dogs 2 — i.e. symptomatic control with Apoquel doesn't address the underlying dysbiosis, if one accepts the causal model.

Caveats worth noting

• Negative studies exist. A WHWT cohort using both shotgun metagenomic sequencing and qPCR found no significant differences were observed in alpha or beta diversity, and no significant abundance of bacterial taxa was identified between allergic and healthy dogs. The Dysbiosis Index (DI) did not differ between the allergic and healthy group. 4 Small (n=21), single-breed, but a real reminder that the picture isn't uniform.
• Breed-specific signatures. Most positive studies are within-breed (Shiba Inu, mixed-breed cohorts). Cross-breed extrapolation is not yet supported.
• Causality vs association. Almost all canine work to date is cross-sectional or short-interventional. Whether dysbiosis causes cAD or is a downstream consequence (of pruritus-related stress, antibiotic exposure, secondary infections, altered diet) remains open.

Sources

1. Song et al. 2025 BMC Microbiology — Probiotics ameliorate atopic dermatitis by modulating gut dysbiosis in dogs
2. Rostaher et al. 2022 Animals — Comparison of the gut microbiome between atopic and healthy dogs (preliminary data)
3. Thomsen et al. 2023 Microbiome — Comprehensive analysis of gut and skin microbiota in cAD in Shiba Inu dogs
4. Rodriguez-Campos et al. 2025 — Gut microbiota of healthy and allergic West Highland White Terriers (negative cohort, n=21)
5. Craig 2016 Veterinary Medicine and Science — Atopic dermatitis and the intestinal microbiota in humans and dogs (review)
6. Selçuk University 2024 — Investigation of cAD and intestinal epithelial damage (small pilot, n=26 cAD)
7. AJVR 2025 — Fecal bacterial microbiota in cAD and clinical recovery after meat-exclusion diet